Accretion Pharmaceuticals Ltd. · NSE:ACCPL
Accretion Pharmaceuticals — H1 FY26 Earnings Presentation
37 slides from Accretion Pharmaceuticals's earnings presentation, Nov 17, 2025
Slide 1: Cover letter to NSE on investor presentation
Date: 17th November, 2025 To, Corporate Relations Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Company Code: ACCPL Dear Sir/ Madam, Subject: Investors/ Analysts Presentation for the half year ended on 30th Septem
Slide 2: Investor Presentation November 2025
Pharmaceuticals Limited Investor Presentation November 2025
Slide 3: Disclaimer
Disclaimer This presentation contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Accretion Pharmaceuticals Limited (APL) and its group companies’ future business developments and
Slide 4: Table of Content
Table of Content Company Overview Business Overview Industry Overview Financial Highlights Way Ahead
Slide 5: Company Overview
Company Overview
Slide 6: Accretion at a glance
Accretion at a glance Leading manufacturer of high-quality Experienced Management Team Modern manufacturing facility Certifications pharmaceutical formulations and Headquartered in Ahmedabad, WHO- cGMP, GLP, Cambodia GMP, Significant experience in contract development manufacturing Gujarat Rwa
Slide 7: Vision & Mission
Vision & Mission Vision To become India’s most trusted and innovative CDMO partner, empowering global and domestic pharmaceutical companies to deliver high-quality medicines to patients faster, safely, and at scale. Mission Our mission is to deliver reliable, end-to-end development and manufacturing
Slide 8: Journey So Far
Journey So Far Listed on the National Stock Exchange (NSE) SME Platform in mid- May 2025 2025 Received cGMP (Current Good Manufacturing Practices) approval from regulatory authorities of Malawi & Nigeria for its manufacturing facility 2024 Received cGMP (Current Good Manufacturing Practices) a
Slide 9: Experienced Management Team
Experienced Management Team Mr. Vivek Ashok Kumar Patel Mr. Harshad Nanubhai Rathod Mr. Hardik Mukundbhai Prajapati Mr. Mayur Popatlal Sojitra Ms. Roshni Shah Promoter and Managing Promoter, Executive Promoter and Executive Promoter and Executive Company Secretary & Director Director & CFO Director
Slide 10: Key Strengths
Key Strengths Visionary Leadership Over decade of experience in this business supported by team of professionals having knowledge of our Strong Relationships various business functions Long-standing relationships with clients and suppliers fostering loyalty and industry reputation Collects fee
Slide 11: Business Overview
Business Overview
Slide 12: Our Comprehensive Therapeutic Offerings
Our Comprehensive Therapeutic Offerings Key Key Product by Dosage Therapeutic Therapeutic Dosage Forms Forms Segment Segments Anti Malarial Tablets Antifungal & Anti Bacterial Anti Inflammatory Antihistamine Capsules Antiallergics Antibiotic Oral Liquids Antitussives Anticold
Slide 13: Dosage Forms - Tablets
Dosage Forms - Tablets Revenue Contribution (Rs. In Crore) Antibiotic 20.9 Antibacterial 12.2 13.4 Antifungal 10.0 Anti- Inflammatory Antihistamine FY22 FY23 FY24 FY25 Antiallergics Capacity and Capacity Utilization Antitussives (Crore) Anticold Antiulcer and Antacid Utilized Capacity, 39.55 Anti-Di
Slide 14: Dosage Forms - Capsules
Dosage Forms - Capsules Revenue Contribution (Rs. In Crore) 9.1 Antibacterial 4.8 5.4 3.9 Antifungal FY22 FY23 FY24 FY25 Anti- Inflammatory Capacity and Capacity Utilization (Crores) Antiulcer and Antacid Utilized Capacity, 9.53 47.63% Cardiac and Anti-Hypertensive Utilizations Vitamins and Suppleme
Slide 15: Dosage Forms – Oral Liquids
Dosage Forms – Oral Liquids Revenue Contribution (Rs. In Crore) Antibiotic 11.8 Antibacterial 10.0 8.5 6.3 Antifungal Antihistamine FY22 FY23 FY24 FY25 Antiallergics Antitussives Capacity and Capacity Utilization (Crores) Anticold Antiulcer and Antacid Utilized Capacity, 1.11 Vitamins and Supplement
Slide 16: Dosage Forms – External Preparations
Dosage Forms – External Preparations Revenue Contribution (Rs. In Crore) Antibiotic 9.9 Antibacterial 3.8 2.9 1.9 FY22 FY23 FY24 FY25 Antifungal Capacity and Capacity Utilization (Crores) Anti-Inflammatory Utilized Capacity, 0.41 Antipruritic 45.04% Utilizations Antiulcer Installed Antiseptic Capaci
Slide 17: Dosage Forms – Oral Powders
Dosage Forms – Oral Powders Revenue Contribution (Rs. In Crore) 5.7 Antibiotic Antibacterial 0.9 1.0 0.2 Antifungal FY22 FY23 FY24 FY25 Antihistamine Capacity and Capacity Utilization Antiallergics (Crores) Utilized Capacity, 3.74 Antitussives 24.91% Anticold Utilizations Antiulcer and Antacid Vitam
Slide 18: With state of art manufacturing facility
…With state of art manufacturing facility Manufacturing facility Granulation Liquid Filling & Sealing Micro lab QC lab QC lab HPLC Tableting Machine Plant Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat External Dosage Tablet Capsules Oral Liquid Oral Pow
Slide 19: Creating Strong Global Presence since 2012
…Creating Strong Global Presence since 2012 International Direct network across 30 countries Africa, Southeast Asia, and Latin America Countries exported through Merchant Exporters include Congo, Libya, Angola, Botswana, Venezuela and Cambodia More than 70 merchant exporters Domestic Domes
Slide 20: Our Certification
Our Certification Accreti@n Pharmaceuticals Limited a Certificate of Registration 19
Slide 21: Reward & Recognition
a Accreti@n Reward & Recognition secrete Glam India Event
Slide 22: Industry Overview
Industry Overview
Slide 23: India: Pharmacy of the World
India : Pharmacy of the World Indian Pharmaceutical Industry Exports ($ billion) Global Pharmaceutical Market (Us $ Billion) The Indian Pharma industry is the world’s 3rd largest by 30.4 3148.31 27.9 volume and 14th by value 24.6 25.4 22.4 1661.26 1763.90 FY 2024-25 turnover: Rs. 2,26,000 Cr, growth
Slide 24: CDMO Industry Overview
CDMO Industry Overview Global CDMO Industry Indian CDMO Industry Role & Importance of CDMOs • End-to-end services from drug development to commercial production, helping India’s CDMO sector is set to double from USD 7B to USD 14 pharma firms cut costs, scale faster, and access advanced technologies
Slide 25: Financial Overview
Financial Overview
Slide 26: Management Comment
Management Comment “H1 FY26 has been a period of strong and disciplined growth. We delivered revenue of ₹43.74 crore, up 135.59% YoY, EBITDA (excluding Other Income) of ₹7.07 crore, up 62.94% YoY, and PAT of ₹4.75 crore, up 92.81% YoY. This robust performance reflects the strength of our integrated
Slide 27: Revenue Break Up – H1FY26
Revenue Break Up – H1FY26 Vertical-wise Revenue Break-up Product-wise Revenue Break-up Direct Export Oral Powder, Sales, 9.2% 12.0% External Domestic Preparation, Sales, 22.9% 16.8% Tablets, 33.9% Sales on Contract Manufacturing Oral Liquid, /Sales Loan 21.1% License, 67.9% Capsules, 16.2% 26 26
Slide 28: Half Yearly Financial Highlights
Half Yearly Financial Highlights Particulars (Rs. in Crore) H1 FY26 H1 FY25 YoY% H2 FY25 Total Income from Operations 43.74 18.56 135.59% 38.81 Revenue in H1 FY26 stood at Rs. 43.74 Raw Materials 32.15 11.98 27.93 crore, up 135.59% YoY, driven by IPO- Employee Cost 2.06 1.54 2.13 funded capex, a ric
Slide 29: Revenue Break Up – FY25
Revenue Break Up – FY25 Vertical-wise Revenue Break-up Product-wise Revenue Break-up Direct Export Oral Powder, Sales, 8.3% 10.0% External Preparation, Domestic 17.2% Sales, 29.3% Tablets, 36.4% Sales on Contract Manufacturing Oral Liquid, /Sales Loan 20.6% License, 62.4% Capsules, 15.8% 28 28
Slide 30: Financial Highlights - Annually
Financial Highlights - Annually Revenue (Rs. Cr) *EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 14 22.3% 25% 8 11.8% 14% 20.7% 11.5% 12 7 12% 20% 57.4 10 11.9 6 6.8 10% 15% 5 8 8% 4 33.7 7.5 6% 29.4 6 7.4% 6.8% 10% 3 3.9 22.3 4 4% 2 5% 0.4% 0.4% 2% 2 1 1.6 2.0 0.1 0.1 0 0% 0 0% FY22 FY23 FY
Slide 31: Annual Financial Highlights
Annual Financial Highlights Particulars (Rs. in Crore) FY25 FY24 FY23 FY22 Total Income from Operations 57.38 33.67 29.38 22.29 Raw Materials 39.91 21.61 23.35 17.56 Employee Cost 3.67 2.62 2.47 1.96 Other Expenses 1.91 1.95 1.57 1.13 Total Expenditure 45.50 26.18 27.39 20.65 EBITDA (Excl. Other Inc
Slide 32: Balance Sheet Highlights
Balance Sheet Highlights Rs. Crore Rs. Crore Liabilities FY25 FY24 FY23 FY22 Assets FY25 FY24 FY23 FY22 Shareholder’s Funds 15.29 5.35 3.84 3.08 Non-current assets 6.33 5.46 6.05 5.86 Share capital 8.17 4.00 3.84 3.08 Property,Plant & Equipment 6.09 5.27 6.01 5.84 Reserves & Surplus 7.12 1.35 0.00 0
Slide 33: Key Ratios
Key Ratios RoE(%) RoA(%) 72.5% 17.0% 14.3% 44.4% 2.6% 2.7% 0.5% 0.5% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 RoCE(%) Total Debt to Equity Ratio (X) 36.5% 38.1% 2.5 2.5 2.2 10.5% 0.9 9.8% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 RoE = Net Profit/Total Equity | RoA = Net Profit/Total Assets / RoCE = EB
Slide 34: Working Capital Analysis (Days)
Working Capital Analysis (Days) Inventory Receivables 74 72 156 131 112 66 96 62 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Payables Net Working Capital 157 147 145 128 116 73 79 48 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 33 33
Slide 35: Way Ahead
Way Ahead
Slide 36: Way Forward
Way Forward Geographical Diversification Strengthening presence across Asia and Africa by moving from merchant exports to direct market engagement 01. Driving growth through expanded product registrations and local distributors to deliver high-quality pharmaceuticals sustainably New Product Deve
Slide 37: Thank You
Thank You Company : Investor Relations Advisors : Accretion Pharmaceuticals Limited. Adfactors PR Pvt. Ltd. CS Roshni Shah Mr. Rupesh Rege / Ms. Ashama Rajawat rupesh.rege@adfactorspr.com compliance@accretionpharma.com ashama.rajawat@adfactorspr.com www.accretionpharma.com www.adfactorspr.com
Accretion Pharmaceuticals — H1 FY26 Earnings Presentation on 6ix